Rimegepant for migraine: acute efficacy beyond the USA
- PMID: 37210086
- DOI: 10.1016/S1474-4422(23)00160-6
Rimegepant for migraine: acute efficacy beyond the USA
Conflict of interest statement
I have received royalties, honoraria, research, and travel grants from Abbvie, Genesis Pharma, Eli Lilly, Lundbeck, Merk, Novartis, Pfizer, Roche, Sanofi, and Teva. I have participated in clinical trials for Abbvie, Eli Lilly, Genesis Pharma, Lundbeck, Novartis, and Teva as principal investigator. I have received payment for expert testimony from Pfizer. I am currently the President of the board of the Hellenic Headache Society and co-chairman of the management group of the Headache Panel at the European Academy of Neurology.
Comment on
-
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Neurol. 2023 Jun;22(6):476-484. doi: 10.1016/S1474-4422(23)00126-6. Lancet Neurol. 2023. PMID: 37210098 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
